Patient diaries as a clinical endpoint in Parkinson's disease clinical trials.

  title={Patient diaries as a clinical endpoint in Parkinson's disease clinical trials.},
  author={Spyridon Spyros Papapetropoulos},
  journal={CNS neuroscience & therapeutics},
  volume={18 5},
Parkinson's disease (PD) is the second most common neurodegenerative disorder with an estimated 4 million patients worldwide. L-dopa is standard, and often initial, therapy for patients with this condition; however, with continued dopaminergic treatment and as the disease progresses, the majority of patients experience complications such as "wearing-off" symptoms, dyskinesias, and other motor complications. These complications may become disabling and profoundly affect quality of life… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 32 extracted citations


Publications referenced by this paper.
Showing 1-10 of 72 references

Members of the UPDRS Development Committee. Unified Parkinson’s disease rating scale

  • S Fahn, RL Elton
  • Calne DB, editors. Recent developments in…
  • 1987
Highly Influential
4 Excerpts

Tolcapone International Parkinson’s Disease Study (TIPS) Group Efficacy and safety of tolcapone in levodopa-treated Parkinson’s disease patients with ’wearing-off

  • VV Myllyla, M Jackson, JP Larsen, H Baas
  • CNS Neuroscience & Therapeutics
  • 2011

Methods for assessing motor fluctuations in conducting clinical trials of antiparkinson agents

  • JM Cedarbaum, M Silvestri
  • Parkinson ’ s disease and the problems of…
  • 2007

Similar Papers

Loading similar papers…